ITPC-MENA
Contact us
Study : Évaluation du cadre légal en matière de propriété intellectuelle et impact sur l'accès aux médicaments (Égypte, Maroc, Tunisie)
Intellectual property and access to medicines

Évaluation du cadre légal en matière de propriété intellectuelle et impact sur l'accès aux médicaments (Égypte, Maroc, Tunisie)

Type
Study
Published
2023
Countries
Morocco, Egypt, Tunisia
Language
Français

This study examines the legal provisions that may facilitate or restrict access to medicines in Egypt, Morocco and Tunisia. It focuses on patentability, the duration of monopolies, compulsory licensing, parallel imports, data exclusivity, and the links between patents and marketing authorisations. Each provision is qualitatively assessed and scored to identify the available legal flexibilities for improving access to medicines.

Available versions

  • Évaluation du cadre légal en matière de propriété intellectuelle et impact sur l'accès aux médicaments (Égypte, Maroc, Tunisie)FrançaisPDF · 2.8 MB

On the same topic

Intellectual property and access to medicines

Étude relative aux lois affectant la production locale de médicaments et autres produits de santé au Maroc

Study2026· Morocco

This study examines the legal, regulatory and economic factors affecting local pharmaceutical production in Morocco, including marketing authorisations, pricing, taxation, intellectual property and investment. Despite a relatively comprehensive regulatory framework and an established pharmaceutical industry, significant barriers remain, limiting the growth of local production and its export potential.

FrançaisPDF · 3.8 MB

Intellectual property and access to medicines

Étude de marché sur les ARV, AAD, Antituberculeux, COVID-19, réactifs et autres maladies opportunistes

Study2023· Morocco

In collaboration with the Ministry of Health and Social Protection, this study examines the availability, marketing, manufacturing and importation of medicines and diagnostic reagents used in Morocco to address HIV, tuberculosis, hepatitis C, COVID-19 and opportunistic infections. It highlights reliance on imports across several therapeutic categories, particularly antiretroviral medicines.

FrançaisPDF · 3.2 MB